Not exact matches
The resulting 2724 trials were then categorized and core information collated, including: trial phase,
cell source (autologous /
allogeneic), current activity of the trial and responsible national regulatory agency.
Initially, and during the first 10 - 15 years of cord blood transplantation, cord blood was predominantly used as a
source of
allogeneic donor
cells.
Our platform includes two distinct approaches to create these vaccines: AST - VAC1, an autologous (patient - specific) vaccine based on
cells sourced from the patient, and AST - VAC2, an
allogeneic (non-patient specific) vaccine manufactured from our proprietary pluripotent stem
cell platform.